SEARCH

SEARCH BY CITATION

References

  • Anasetti, C., Hansen, J.A., Waldmann, T.A., Appelbaum, F.R., Davis, J., Deeg, H.J., Doney, K., Martin, P.J., Nash, R., Storb, R., Sullivan, K.M., Witherspoon, R.P., Binger, M.H., Chizzonite, R., Hakimi, J., Mould, D., Satoh, H. & Light, S.E. (1994) Treatment of acute graft-versus-host disease with humanized anti-tac: an antibody that binds to the interleukin-2 receptor. Blood, 84, 13201327.
  • Blaise, D., Olive, D., Michallet, M., Marit, G., Leblond, V. & Maraninchi, D. (1995) Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis. Lancet, 345, 11441146.
  • Hengster, P., Pescovitz, M.D., Hyatt, D. & Margreiter, R. (1999) Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for the prevention of renal allograft rejection. Transplantation, 68, 310313.
  • Langrehr, J.M., Nüssler, N.C., Neumann, U., Guckelberger, O., Lohmann, R., Radtke, A., Jonas, S., Klupp, J., Steinmüller, T., Lobeck, H., Meuer, S., Schlag, H., Lemmens, H.P., Knoop, M., Keck, H., Bechstein, W.O. & Neuhaus, P. (1997) A prospective randomized trial comparing interleukin-2 receptor antibody versus antithymocyte globulin as part of a quadruple immunosuppressive induction therapy after orthotopic liver transplantation. Transplantation, 63, 17721781.
  • Mariat, C., Alamartine, E., Diab, N., De Filippis, J.P., Laurent, B. & Berthoux, F. (1998) A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients. Transplantation International, 11, 231236.
  • Mattson, J., Rindgen, O., Aschan, J., Barkholt, L., Dalianis, T., Hagglund, H., Ljungman, P., Lonnqvist, B., Tollemar, J., Winiarski, J. & Remberger, M. (1997) A low incidence of grade II to IV acute GVHD, but high mortality from infection using HLA-A,-B, and -DR-identical unrelated donors and immunosuppression with ATG, ciclosporine, and methotrexate. Transplantation Proceedings, 29, 735736.DOI: 10.1016/s0041-1345(96)00444-7
  • Nademanee, A., Schmidt, G.M., Parker, P., Dagis, A.C., Stein, A., Snyder, D.S., O'Donnell, M., Smith, E.P., Stepan, D.E. & Molina, A. (1995) The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone. Blood, 86, 12281234.
  • Przepiorka, D., Kernan, N.A., Ippoliti, C., Papadopoulos, E.B., Giralt, S., Khouri, I., Lu, J.G., Gajewski, J., Durett, A., Cleary, K., Champlin, R., Andersson, B.S. & Light, S. (2000) Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood, 95, 8389.
  • Storb, R., Pepe, M., Anasetti, C., Appelbaum, F.R., Beatty, P., Doney, K., Martin, P., Stewart, P., Sullivan, K.M. & Witherspoon, R. (1990) What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? Blood, 76, 10371045.
  • Van Lint, M.T., Uderzo, C., Locasciulli, A., Majolino, I., Scimé, R., Locatelli, F., Giorgiani, G., Arcese, W., Iori, A.P., Falda, M., Bosi, A., Miniero, R., Alessandrino, P., Dini, G., Rotoli, B. & Bacigalupo, A. (1998) Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood, 92, 22882293.
  • Weisdorf, D., Haake, R., Blazar, B., Miller, W., McGlave, P., Ramsay, N., Kersey, J. & Filipovich, A. (1990) Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood, 75, 10241030.
  • Witherspoon, R.P., Deeg, H.J. & Storb, R. (1994) Secondary malignancies after marrow transplantation for leukemia or aplastic anemia. Transplantation Science, 4, 3341.